Home » USP CEO Roger L. Williams, M.D., to Step Down in 2014
USP CEO Roger L. Williams, M.D., to Step Down in 2014
USP chairman of the Board of Trustees Duane M. Kirking, Pharm.D., Ph.D., announced that Roger L. Williams, M.D., CEO and chair of the Council of Experts for the United States Pharmacopeial Convention (USP), will step down on June 30, 2014, in accordance with previously agreed contractual commitments.
“Dr. Williams has made strong contributions to USP through his leadership,” Dr. Kirking said. “During his tenure, USP's public health activities and impact have increased significantly, with USP’s quality standards now used in more than 140 countries. In addition, USP’s presence in the world has expanded through laboratories, offices and training centers in the U.S. and in six other countries” (India, China, Brazil, Switzerland, Ethiopia and Ghana).
Dr. Williams joined USP in early 2000. As chief executive officer, Dr. Williams provides strategic leadership for USP at the direction of its Board of Trustees. Dr. Williams also serves as chair of the Council of Experts, USP’s scientific standards-setting body, which continuously revises USP’s seven compendia of standards, including the United States Pharmacopeia and the National Formulary, USP on Compounding, Medicines Compendium, Herbal Medicines Compendium, Dietary Supplements Compendium and Food Chemicals Codex. Dr. Williams also leads USP’s outreach efforts to national and international bodies that share USP's public health mission.
Dr. Williams is USP’s fourth ceo. His predecessors were Dr. Lloyd Miller (1950-1970), Dr. William Heller (1970-1990) and Mr. Jerry Halperin (1990-2000). He is the 15th chair of the Council of Experts, the first being a physician, Dr. Lyman Spalding, who chaired the USP Committee of Revision (now the Council of Experts) beginning in 1820. Dr. Williams also is a physician with a career that focused on the pharmaceutical sciences first at the University of California, San Francisco (1977-1990), then at FDA (1990-2000).
The Executive Committee of the Board of Trustees plans to announce the selection of an executive search firm and a search committee by the end of January 2013.
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
- All news »